口腔癌的免疫治疗
Immunotherapy in Oral Cancer.
作者信息
Mohan Sunil Paramel, Bhaskaran Manoj K, George Ashford L, Thirutheri Abhilash, Somasundaran Maya, Pavithran Anegh
机构信息
Department of Oral and Maxillofacial Pathology, Sree Anjaneya Institute of Dental Sciences, Calicut, Kerala, India.
Department of Oral and Maxillofacial Surgery, Sree Anjaneya Institute of Dental Sciences, Calicut, Kerala, India.
出版信息
J Pharm Bioallied Sci. 2019 May;11(Suppl 2):S107-S111. doi: 10.4103/JPBS.JPBS_31_19.
Abstract
Immunotherapy is one of the newer entities which is promising, at least can be very much helpful as an adjuvant therapy. This newer modality of the treatment in the field of cancer treatment may be the fourth pillar supporting surgery, chemotherapy, and radiotherapy. Careful selection of patient is the key for success of immunotherapy, which is based on patient's immunological contexture. This review aimed to present the fundamental aspects of tumor immunity and immunotherapy, focused on oral squamous cell carcinoma.
摘要
免疫疗法是较新的、有前景的治疗方法之一，至少作为辅助疗法会非常有帮助。这种癌症治疗领域的新型治疗方式可能会成为支撑手术、化疗和放疗的第四大支柱。仔细挑选患者是免疫疗法成功的关键，这基于患者的免疫结构。本综述旨在介绍肿瘤免疫和免疫疗法的基本方面，重点是口腔鳞状细胞癌。
相似文献
1
Immunotherapy in Oral Cancer.
J Pharm Bioallied Sci. 2019 May;11(Suppl 2):S107-S111. doi: 10.4103/JPBS.JPBS_31_19.
2
Tumour Microenvironment as a Potential Immune Therapeutic Target for Tongue Cancer Management.
J Oral Maxillofac Pathol. 2023 Apr-Jun;27(2):382-389. doi: 10.4103/jomfp.jomfp_134_23. Epub 2023 Jul 13.
3
The role of radiotherapy in the age of immunotherapy.
Jpn J Clin Oncol. 2021 Apr 1;51(4):513-522. doi: 10.1093/jjco/hyaa268.
4
Effective combinations of radiotherapy and immunotherapy in the treatment of esophageal squamous cell carcinoma.
Future Oncol. 2020 Nov;16(31):2537-2549. doi: 10.2217/fon-2020-0222. Epub 2020 Oct 27.
5
Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma: Current Status and Challenges.
Front Oncol. 2021 Mar 8;11:616629. doi: 10.3389/fonc.2021.616629. eCollection 2021.
6
Radiation and Immunotherapy in Upper Gastrointestinal Cancers: The Current State of Play.
Int J Mol Sci. 2021 Jan 22;22(3):1071. doi: 10.3390/ijms22031071.
7
Long-term survival of a patient with recurrent gallbladder carcinoma, treated with chemotherapy, immunotherapy, and surgery: a case report.
Surg Case Rep. 2018 Sep 15;4(1):115. doi: 10.1186/s40792-018-0512-6.
8
Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker?
Front Immunol. 2021 Nov 4;12:745146. doi: 10.3389/fimmu.2021.745146. eCollection 2021.
9
Immune contexture defined by single cell technology for prognosis prediction and immunotherapy guidance in cancer.
Cancer Commun (Lond). 2019 Apr 18;39(1):21. doi: 10.1186/s40880-019-0365-9.
10
Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy.
Cancer Lett. 2019 Jun 28;452:66-70. doi: 10.1016/j.canlet.2019.02.048. Epub 2019 Mar 19.
引用本文的文献
1
Evaluation of Programmed Death-Ligand 1 (PD-L1) Expression and Its Correlation With Clinicopathological Parameters in Oral Squamous Cell Carcinoma: A Tertiary Care Center Study.
Cureus. 2025 Jun 1;17(6):e85186. doi: 10.7759/cureus.85186. eCollection 2025 Jun.
2
PD-L1/PD-1 Expression in the Treatment of Oral Squamous Cell Carcinoma and Oral Potentially Malignant Disorders: An Overview of Reviews.
J Pers Med. 2025 Mar 25;15(4):126. doi: 10.3390/jpm15040126.
3
Reverse Vaccinology and Immunoinformatics Strategy to Screen Oncogenic Proteins and Development of a Multiepitope Peptide Vaccine Targeting Protein Kinases against Oral Cancer: An in-silico Study.
Asian Pac J Cancer Prev. 2024 Nov 1;25(11):4067-4080. doi: 10.31557/APJCP.2024.25.11.4067.
4
Epidemiology, Diagnostics, and Therapy of Oral Cancer-Update Review.
Cancers (Basel). 2024 Sep 14;16(18):3156. doi: 10.3390/cancers16183156.
5
Identification of effective diagnostic genes and immune cell infiltration characteristics in small cell lung cancer by integrating bioinformatics analysis and machine learning algorithms.
Saudi Med J. 2024 Aug;45(8):771-782. doi: 10.15537/smj.2024.45.8.20240170.
6
The role of periodontitis in cancer development, with a focus on oral cancers.
Mol Biol Rep. 2024 Jul 15;51(1):814. doi: 10.1007/s11033-024-09737-6.
7
Dysbiosis linking periodontal disease and oral squamous cell carcinoma-A brief narrative review.
Heliyon. 2024 May 31;10(11):e32259. doi: 10.1016/j.heliyon.2024.e32259. eCollection 2024 Jun 15.
8
Immunotherapy: The Fourth Domain in Oral Cancer Therapeutics.
Indian J Otolaryngol Head Neck Surg. 2024 Jun;76(3):2257-2272. doi: 10.1007/s12070-024-04565-3. Epub 2024 Mar 10.
9
miR-362-3p inhibited the invasion and metastasis of oral squamous cell carcinoma cells by targeting the regulation of pituitary tumor-transforming gene 1.
Hua Xi Kou Qiang Yi Xue Za Zhi. 2024 Feb 1;42(1):46-55. doi: 10.7518/hxkq.2024.2023237.
10
The Potential Mechanism of Curcumin in Treating Oral Squamous Cell Carcinoma Based on Integrated Bioinformatic Analysis.
Int J Genomics. 2023 Oct 14;2023:8860321. doi: 10.1155/2023/8860321. eCollection 2023.
本文引用的文献
1
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.
J Clin Oncol. 2017 Mar;35(7):785-792. doi: 10.1200/JCO.2015.66.1389. Epub 2016 Nov 14.
2
Advances in Cancer Immunotherapy in Solid Tumors.
Cancers (Basel). 2016 Nov 24;8(12):106. doi: 10.3390/cancers8120106.
3
Radiation Therapy Plus Anti-Programmed Death Ligand 1 Immunotherapy: A Review on Overall Survival.
Radiol Technol. 2016 Sep;88(1):123-8.
4
NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?
J Immunol Res. 2016;2016:4684268. doi: 10.1155/2016/4684268. Epub 2016 May 12.
5
Prospects for gene-engineered T cell immunotherapy for solid cancers.
Nat Med. 2016 Jan;22(1):26-36. doi: 10.1038/nm.4015.
6
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
7
LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model.
Oncotarget. 2015 Sep 29;6(29):27359-77. doi: 10.18632/oncotarget.4751.
8
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.
9
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.
10
Pembrolizumab for the treatment of non-small-cell lung cancer.
N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19.
Zotero 插件